dc.contributor.author | Bilgin, Emre | |
dc.contributor.author | Ozarli, İrem | |
dc.contributor.author | Kılıc, Levent | |
dc.contributor.author | Bolek, Ertuğrul Çagrı | |
dc.contributor.author | Yardımcı, Gözde Kübra | |
dc.contributor.author | Karadağ, Ömer | |
dc.date.accessioned | 2021-03-16T13:16:37Z | |
dc.date.available | 2021-03-16T13:16:37Z | |
dc.date.issued | 2018-11-24 | |
dc.identifier.citation | Bilgin E, Ozarli İ, Kılıç L, Bölek EÇ, Yardımcı GK, Karadağ Ö. Some concerns from Turkey. Ann Rheum Dis. 2020 Feb;79(2):e15. doi: 10.1136/annrheumdis-2018-214739. Epub 2018 Nov 24. PMID: 30472654. | tr_TR |
dc.identifier.uri | http://hdl.handle.net/11655/23565 | |
dc.identifier.uri | http://dx.doi.org/10.1136/annrheumdis-2018-214739 | |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/30472654/ | |
dc.description.abstract | We read the paper written by Kaneko et al with great interest.1 This study demonstrates the safety and efficacy of tocilizumab in patients with adult-onset Still’s disease (AOSD). This randomised placebo-controlled study could be one of the pioneer studies about the use of biological therapy in AOSD. We wanted to ask about some raising concerns | tr_TR |
dc.language.iso | en | tr_TR |
dc.publisher | BMJ | tr_TR |
dc.relation.isversionof | 10.1136/annrheumdis-2018-214739 | |
dc.rights | info:eu-repo/semantics/openAccess | tr_TR |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.subject | NSAIDs | tr_TR |
dc.subject | Adult-onset Still’s disease | tr_TR |
dc.subject | Corticosteroids | tr_TR |
dc.subject.lcsh | Tıp uygulaması | tr_TR |
dc.title | Some concerns from Turkey | tr_TR |
dc.type | info:eu-repo/semantics/article | tr_TR |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Ann Rheum Dis | tr_TR |
dc.contributor.department | İç Hastalıkları | tr_TR |
dc.identifier.volume | 79 | tr_TR |
dc.description.index | PubMed | tr_TR |
dc.funding | Yok | tr_TR |